Sveriges mest populära poddar
Pharmaceutical Executive
VetenskapLife Science

Pharmaceutical Executive Daily: FDA Approves Hepcludex

3 min•26 maj 2026
In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA approves Hepcludex as the first treatment for chronic hepatitis delta virus infection in the United States, and biotech finance leaders reflect on the lessons learned from navigating two decades of volatile markets.

Fler avsnitt av Pharmaceutical Executive

Visa alla avsnitt av Pharmaceutical Executive
Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization
•3 min
Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge
•3 min
Pharmaceutical Executive Daily: FDA Names Seven Participants to Precheck Program
•3 min
Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics
•4 min
Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
•3 min
Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration
•3 min
Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts
•4 min
Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion
•3 min
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
•4 min
Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive
•4 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.